Category:
Anti-tumor Preparations
CAS NO:
25316-40-9
Standard:
ChP,USP,In-house Standards,

It is indicated for:
1. The treatment of metastatic carcinoma of the ovary in patients with disease that
is refractory to both paclitaxel- and platinum-based chemotherapy regimens.
Refractory disease is defined as disease that has progressed while on
treatment, or within 6 months of completing treatment.
2. The treatment of AIDS-related Kaposi’s sarcoma in patients with disease that
has progressed on prior combination chemotherapy or in patients who are
intolerant to such therapy.